We observed lower incidences of KDD in ERBB2, ERBB3 and ERBB4 than EGFR, with distributions mirroring those of other observed oncogenic mutations in brain tumors and NSCLC13–17 (Table 1a). This evidence concerns the gene ERBB4 and brain neoplasm.